-
公开(公告)号:US20220363707A1
公开(公告)日:2022-11-17
申请号:US17266521
申请日:2019-08-05
发明人: Michelle Machacek , David Witter , Craig Gibeau , Chunhui Huang , Shuhei Kawamura , David L. Sloman , Phieng Siliphaivanh , Ryan Quiroz , Murray Wan , Sebastian Schneider , Charles S. Yeung , Michael H. Reutershan , Timothy J. Henderson , Jean-Laurent Paparin , Houcine Rahali , Jonathan M. E. Hughes , Sulagna Sanyal , Yingchun Ye , David A. Candito , Patrick S. Fier , Steven M. Silverman
IPC分类号: C07H19/14 , C07D487/04 , A61P35/00
摘要: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
-
公开(公告)号:US20210309687A1
公开(公告)日:2021-10-07
申请号:US17266515
申请日:2019-08-05
申请人: Michelle MACHACEK , David WITTER , Chunhui HUANG , Shuhei KAWAMURA , Sebastian SCHNEIDER , Mrray WAN , Merck Sharp & Dohme Corp.
发明人: Michelle Machacek , David Witter , Chunhui Huang , Shuhei Kawamura , Sebastian Schneider , Murray Wan
摘要: The present invention provides a compound of formula (I) Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, are PRMT5 inhibitors. Also provided are methods of making compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I), and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
-
公开(公告)号:US20210277009A1
公开(公告)日:2021-09-09
申请号:US17266474
申请日:2019-08-05
申请人: David WITTER , Shuhei KAWAMURA , Michelle MACHACEK , Ryan QUIROZ , Michael H. REUTERSHAN , Sebastian SCHNEIDER , Phieng SILIPHAIVANH , Yingchun YE , Charles S. YEUNG , Merck Sharp & Dohme Corp.
发明人: David Witter , Shuhei Kawamura , Michelle Machacek , Ryan Quiroz , Michael H. Reutershan , Sebastian Schneider , Phieng Siliphaivanh , Yingchun Ye , Charles S. Yeung
IPC分类号: C07D487/04 , C07D519/00
摘要: The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
-
公开(公告)号:US20210309688A1
公开(公告)日:2021-10-07
申请号:US17266507
申请日:2019-08-05
申请人: Jongwon Lim , Michelle Machacek , Michael H. Reutershan , Sebastian Schneider , Merck Sharp & Dohme Corp.
IPC分类号: C07H19/167 , C07D473/34 , C07D471/04
摘要: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
-
-
-